Motilal Oswal
    NIFTY 50
Motilal Oswal

HDFC Securities has a 'buy' call on Sun Pharma, says Lupin valuations attractive

Updated : June 21, 2019 11:21 AM IST

Holding a 'buy' rating on Sun Pharma, Amey Chalke, research analyst at HDFC Securities, said that the observations received at Halol Unit can be resolved.

Pharma stocks are not having a great 2019 with the Nifty pharma index down 10 percent so far this year.

On Lupin, Chalke said, “It is facing a lot of regulatory issues, they have four official actions indicated (OAI) for the plants.”

“The key product approval like ProAir would be the key trigger for the stock to move. However, the price is attractive," he added.

Speaking about largecaps, he said, “We have a target price of more than Rs 3300 on Dr Reddy's because there are no regulatory issues, they are focusing on cost optimisation. There are a lot of product approvals expected in FY20.”

“In midcaps, we like a domestic-focused company like Alkem Laboratories and Abbott India,” he added.
primo org
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more
Live TV